Acadia Pharmaceuticals CEO Catherine Owen Adams is focused on executing near-term growth and building out a pipeline to continue the momentum the company has built in the past year. Owen Adams joined Acadia in September after a lengthy career in big pharma, including most recently overseeing Bristol Myers Squibb’s US business.
Acadia’s New CEO Outlines Growth Strategy
Continuing to grow Nuplazid and Daybue are top priorities along with pipeline and business development, Catherine Owen Adams told Scrip.
More from Strategy
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.